FTFinancial Times·2dHealth
score-0.40
FDA Declines China's Ivonescimab, Testing U.S. Scrutiny of Biotech
Original
FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
“The phrase "blow to" and rejection framing convey negative business implications without invoking fear or catastrophe.”